// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1671 Abstracts

Whole-exome sequencing of single circulating tumor cells is a useful tool for studying the intrapatient genetic heterogeneity in metastatic prostate cancer.

Vincent Faugeroux - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial.

Joaquin Mateo - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Olaparib

Phase I/Ib study of enzalutamide and gemcitabine and cisplatin in bladder cancer.

Shilpa Gupta - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Anti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: results of the CirCe T-DM1 trial

F-C.Bidard - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Trastuzumab emtansine

Single-cell combined mutation and gene expression studies of circulating tumor-associated cells in non-small cell lung cancer

J.Mong - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

TP53

Circulating tumor cells as liquid biopsy for castration resistant prostate cancer patients treated with cabazitaxel

S.Salvi - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Gene expression BIRC5, Erb-b2/Her2-neu, ESR1, PGR1, MMP11, MDR1, MRP1, MXR at the CTCs in the primary breast cancer

Y.Shliakhtunou - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

longitudinal exploratory analysis of prior- surgery everolimus circulating and clinical biomarkers in locally advanced and metastatic renal cell carcinoma patients (RCC)

R.Elaidi - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Everolimus

Relationship between pretreatment levels of circulating DNA, circulating tumor cells, CEA, CA19.9 and tumor burden on CT scan in patients treated for a metastatic colorectal cancer

M.Hassine - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Circulating tumor cells (CTCs), molecular alterations and their correlation with characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated in the Spanish TTD VISNÚ Program

J.Sastre - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma

H.Shoji - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Ramucirumab

Apatinib and irinotecan combination treatment in first-line chemotherapy refractory esophageal squamous cell carcinoma: A phase I dose escalation study

J.Jia - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Irinotecan

Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes

H.Scher - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

taxane

ARV7 status and CTC count: A combined biomarker for the baseline therapeutic decision in each line of mCRPC treatment

E.Bournakis - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A phase II clinical trial of radium-223 activity in patients (pts) with metastatic castration-resistant prostate cancer (mcrpc) with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational status (EXCAAPE)

J.Carles Galceran - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Serial genotypic characterization of circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) undergoing treatment with abiraterone acetate (abi) or enzalutamide (enza)

N.Dizman - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Ex vivo expansion of circulating tumor cells for individualized drug susceptibility in patients with advanced or recurrent oesophageal cancer

V.Kumar - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Exploratory study of CK-M30 and pHH3 expression in Circulating Tumor Cells (CTCs) as biomarkers of docetaxel (DOC) efficacy in metastatic castration resistant prostate cancer (mCRPC)

P.Nombela Blanco - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Mucosal injury of small intestine in patients with advanced gastric cancer who developed chemotherapy induced diarrhea (CID).

Miho Sakumura - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

Capecitabine

Prognostic significance of circulating tumor cells in patients with gastric cancer: Epithelial mesenchymal transition and perioperative kinetics.

Yui Ishiguro - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Copyright © 2026. QuantiNova All rights reserved